Definitive Healthcare's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Definitive Healthcare (DH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Definitive Healthcare vs Its Competitors
- TTM: Trailing 12-month revenue of 233M vs 4,587M combined for tracked competitors (4.8% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-5.1% annualized vs trailing 12 months), vs accelerating (+8.0%) for its tracked peer group.
- Growth: Definitive Healthcare generated -9.1% revenue growth year over year in Q2 2026, vs 17.4% for its tracked competitors combined.
- Profitability: Its -13.5% net margin compares with -29.9% for the peer group.
- Scale: Definitive Healthcare ranks #156 of 259 companies by market capitalization in the Software & Programming industry, holding 0.0% of industry market cap.
- Peer revenue share: Definitive Healthcare accounted for 4.3% of combined revenue among its tracked peer group, down from 5.4% a year earlier.
- Peer differentiation: Revenue per employee of $0.34M compares with $0.20M for the peer group (1.7x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
DH Sales vs. its Competitors, Q2 2026
Definitive Healthcare reported revenue contraction of 9.14 % year on year in Q2 2026, below its competitors' combined revenue growth of 17.38 %.
With a net margin of -13.50 %, Definitive Healthcare achieved higher profitability than its competitors (-29.90 %).
Definitive Healthcare generated 4.27 % of the combined sales of its peer group, down from 5.44 % a year earlier.
Definitive Healthcare vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Definitive Healthcare and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Definitive Healthcare Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Definitive Healthcare's competitor groups requires a Commercial License.
For context: the Software & Programming industry grew revenue 16.4% year over year, combined, vs -9.1% for Definitive Healthcare. Definitive Healthcare's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.
Definitive Healthcare's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Definitive Healthcare Corp | No | No | No | No |
| Competitors combined (3) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) | 12.50 % (1 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
DH Stock Performance relative to its Competitors
DH Stock Performance relative to High-Confidence Competitors
DH Stock Performance relative to Similar-Size Competitors
DH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Iqvia Holdings Inc | 282.9% | Outperformed |
| 2 | Veeva Systems Inc | 282.9% | Outperformed |
| 3 | Zoominfo Technologies Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Definitive Healthcare's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Definitive Healthcare's Comment on Competition and Industry Peers
Proprietary Healthcare-specific Commercial Intelligence. We have built proprietary intelligence via first-party research, aggregated, linked, cleansed and inferred information from thousands of data sources and tied billions of data points together into a comprehensive view of the entire U.S. healthcare ecosystem.
An Integrated Data and Technology Foundation that Creates a Flywheel of Innovation. Our technology platform provides the foundation for rapid product development and innovation by leveraging our existing data assets to produce new modules and features that solve a growing number of business problems.
Powerful Go-to-Market Engine. We have a highly efficient and effective go-to-market engine that combines effective marketing with an inside sales force comprised of highly trained, vertically focused sales executives.
Visionary, Founder-Led Management Team with a Track Record of Execution. Our founder-led management team has a strong track record of exceptional financial performance and of building an award-winning culture to attract and retain highly talented individuals. While we believe no competitor matches our breadth of data and intelligence solutions or offers as comprehensive and accurate a commercial intelligence platform, we compete either directly or indirectly with:
Legacy raw claims data providers, such as Clarivate, IQVIA and Symphony Health;
Niche healthcare specialists, such as Komodo Health, H1 Healthcare, Marketware, Trella Health and Trilliant Health;
Ecosystem players that may house or analyze similar intelligence, such as SG2, and Veeva; and
Horizontal go-to-market intelligence platforms, such as ZoomInfo, LinkedIn and Dun & Bradstreet. We believe the principal competitive factors in our markets are:
Depth, breadth and accuracy of healthcare-specific commercial intelligence;
Healthcare subject matter expertise;
A.I. and data science capabilities;
Ease of use and deployment; and
Data privacy and security.
Publicly Traded Peers of Definitive Healthcare Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Definitive Healthcare Corp | 95.76 | 232.70 |
| Veeva Systems Inc | 47,115.52 | 3,456.71 |
| Iqvia Holdings Inc | 45,650.73 | 16,632.00 |
| Zoominfo Technologies Inc | 1,116.17 | 1,129.90 |
| SUBTOTAL | 93,978.18 | 21,451.31 |
Sources: Definitive Healthcare Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Definitive Healthcare Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Definitive Healthcare's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Forian Inc | Named by the company | 85% |
| Voxx International Corporation | Named by the company | 85% |
| Iqvia Holdings Inc | Named by the company | 85% |
| Veeva Systems Inc | Named by the company | 85% |
| Zoominfo Technologies Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Definitive Healthcare's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Definitive Healthcare's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Veeva Systems Inc | Reportable 100.00 % |
| Iqvia Holdings Inc | Research and Development Solutions 58.90 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Definitive Healthcare's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Definitive Healthcare Corp | 96 | 339,219 | -342,194 |
| Veeva Systems Inc | 47,116 | 436,013 | 127,998 |
| Iqvia Holdings Inc | 45,651 | 178,839 | 14,914 |
| Zoominfo Technologies Inc | 1,116 | 355,314 | -170,126 |
| PEERS TOTAL | 93,882 | 203,813 | 17,873 |
Definitive Healthcare's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Veeva Systems Inc | North America 59.57 % |
| Iqvia Holdings Inc | Americas 48.17 % |
| Zoominfo Technologies Inc | Non-US 12.96 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Definitive Healthcare's Position in Industry Market Structure
Market-capitalization share and concentration across all 235 companies in Definitive Healthcare's industry classification, broader than the peer set above. Market cap in millions of $.Definitive Healthcare ranks #156 of 235 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,648, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Microsoft Corporation | 3,843,736 | 50.18 % |
| 2 | Palantir Technologies Inc | 484,429 | 6.32 % |
| 3 | Oracle Corporation | 397,143 | 5.18 % |
| 4 | Crowdstrike Holdings Inc | 278,764 | 3.64 % |
| 5 | Sap Se | 1,234 | 5.2% |
| 6 | Shopify Inc | 1,234 | 5.2% |
| 7 | Salesforce Inc | 1,234 | 5.2% |
| 8 | Full Truck Alliance Co Ltd | 1,234 | 5.2% |
| 9 | Servicenow Inc | 1,234 | 5.2% |
| 10 | Cloudflare Inc | 1,234 | 5.2% |
| 156 | Definitive Healthcare Corp | 98 | 0.00 % |
Market cap and industry share for the rest of Definitive Healthcare's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.
Definitive Healthcare's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 151 | Domo Inc | 153 | - |
| 152 | Arqit Quantum inc | 124 | -30.48 % |
| 153 | Umeworld Inc | 116 | - |
| 154 | Soundthinking Inc | 112 | -28.95 % |
| 155 | Foresight Autonomous Holdings Ltd | 1,234 | 12.3% |
| 156 | Definitive Healthcare Corp | 98 | -77.18 % |
| 157 | Inspired Entertainment Inc | 1,234 | 12.3% |
| 158 | Quantum X Labs Inc | 1,234 | 12.3% |
| 159 | Carecloud Inc | 1,234 | 12.3% |
| 160 | Audioeye Inc | 1,234 | 12.3% |
| 161 | Fatpipe Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Definitive Healthcare's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Definitive Healthcare's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Software & Programming industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (344 companies). See the full Software & Programming industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 75.24 % | 64.10 % (avg) | +11.1 pp |
| Operating Margin | -104.58 % | industry median | -101.9 pp |
| EBITDA Margin | -62.81 % | 2.54 % (avg) | -65.3 pp |
| Capital Intensity (Capex / Revenue) | 5.53 % | 4.79 % (avg) | +0.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Definitive Healthcare's Valuation vs Competitive Position
Valuation multiples vs the Software & Programming industry average (344 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Software & Programming industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 39.4x | - |
| EV / EBITDA | - | 21.7x | - |
| P/B | 0.3x | 5.4x | -5.1x |
| Return on Equity | -81.85 % | industry aggregate | -107.05 % |
| Return on Invested Capital | -26.69 % | -0.38 % (avg) | -26.31 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Definitive Healthcare's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | 12.92 % | 0.31 % | -4.24 % |
| Operating Margin | - | -19.78 % | -131.18 % | -281.85 % | -92.86 % |
| Return on Invested Capital | - | -1.02 % | -8.76 % | -29.40 % | -19.29 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Definitive Healthcare's Strategic Group Map
Every company in Definitive Healthcare's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Definitive Healthcare is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Definitive Healthcare's BCG Growth-Share Matrix
Relative market share (vs Definitive Healthcare's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Definitive Healthcare falls in the Question Mark quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 11.4% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Microsoft Corporation alone holds 50% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Definitive Healthcare's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 2,648 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 5.53 % vs industry average 4.79 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Definitive Healthcare's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Definitive Healthcare's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Definitive Healthcare's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Definitive Healthcare falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Definitive Healthcare's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 101.9 points below the industry median.
- Return on equity 107.1 points below the industry aggregate.
- Latest-quarter revenue run-rate is decelerating (-5.1% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Industry revenue growing at a healthy 11.4% median pace.
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Industry dominated by Microsoft Corporation, holding 50.18 % of industry market cap.
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Definitive Healthcare's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Definitive Healthcare Corp | 1.04 | 1.71 | 0.57 |
| Veeva Systems Inc | 1.18 | 5.42 | - |
| Iqvia Holdings Inc | 0.24 | 0.76 | 2.47 |
| Zoominfo Technologies Inc | 0.26 | 0.68 | 0.98 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Definitive Healthcare's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Definitive Healthcare Corp | Q2 2026 | -9.1 % | - |
| Veeva Systems Inc | Q2 2026 | +17.6 % | +36.5 % |
| Iqvia Holdings Inc | Q1 2026 | +8.4 % | +10.4 % |
| Zoominfo Technologies Inc | Q2 2026 | +16.6 % | - |
| PEERS TOTAL | +10.1 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Definitive Healthcare's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Definitive Healthcare Corp | Q2 2026 | +66.5 % | +28.3 % |
| Veeva Systems Inc | Q2 2026 | +19.0 % | +27.3 % |
| Iqvia Holdings Inc | Q1 2026 | +10.5 % | -10.6 % |
| Zoominfo Technologies Inc | Q2 2026 | -24.4 % | -20.0 % |
Definitive Healthcare's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Definitive Healthcare Corp | - | - | - |
| Veeva Systems Inc | 11.51% | 13.75% | 14.00% |
| Iqvia Holdings Inc | 4.74% | 5.95% | 22.15% |
| Zoominfo Technologies Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Definitive Healthcare's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Definitive Healthcare Corp | - | 0.41 |
| Veeva Systems Inc | 46.87 | 13.63 |
| Iqvia Holdings Inc | 33.44 | 2.74 |
| Zoominfo Technologies Inc | - | 0.99 |
| PEERS AVERAGE | 57.80 | 4.38 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.